RGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Regenxbio Inc (RGNX) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock is facing significant regulatory challenges, weak financial performance, and negative sentiment from recent news and lawsuits. While there are some positive catalysts in the pipeline, the risks outweigh the potential rewards in the current scenario.
The technical indicators are neutral. The RSI is at 40.706, indicating no clear overbought or oversold condition. The MACD histogram is positive but contracting, suggesting weakening momentum. The stock is trading below the pivot level of 8.702, with key support at 7.995. Overall, the technical setup does not strongly favor a buy.
The company is advancing late-stage pipelines, including RGX-202 for Duchenne muscular dystrophy and ABBV-RGX-314 for wet age-related macular degeneration, which have significant market potential.
Analysts like Stifel and Clear Street maintain a Buy rating, citing the strength of the company's AAV technology and upcoming pivotal data readouts.
The FDA's clinical hold on RGX-111 and the complete response letter for RGX-121 raise safety and regulatory concerns.
Recent lawsuits and investigations into potential investor losses add to negative sentiment.
The stock has experienced significant price declines, with a -3.21% drop in the regular market and -2.52% in pre-market trading.
The company's financial performance in Q4 2025 is weak. Revenue dropped by -84.97% YoY to $3.19M. Net income remains negative at -$67.15M, though it improved by 31.19% YoY. EPS also improved to -1.3, up 28.71% YoY. However, gross margin dropped significantly to -85.89%, down -222.32% YoY, indicating severe profitability challenges.
Analysts have mixed views. Stifel, Clear Street, and H.C. Wainwright maintain Buy ratings with price targets ranging from $32 to $45, citing potential in late-stage pipelines. However, Morgan Stanley and Goldman Sachs have lowered price targets to $17 and $12, respectively, citing regulatory challenges and safety concerns. The consensus reflects cautious optimism but highlights significant risks.
